The effect of Olanzapine on the prevention of radiotherapy-induced nausea and vomiting

Assesment of the effect of Olanzapine on the prevention of radiotherapy-induced nausea and vomiting in patients with abdominal cancers

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170814035697N7

Enrollment

Registered

2022-02-27

Start date

2022-01-15

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiotherapy induced nausea and vomiting. Nausea and vomiting

Interventions

Intervention 1: Intervention group: routine treatment + olanzapine tablets with a dose of 5 mg for patients less than 60 kg and 10 mg for patients over 60 kg one day before the start of radiotherapy u

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Complete the consent form and announce cooperation Age over 18 years Radiotherapy for cancer (patients undergoing chemotherapy or surgery in addition to radiotherapy) Radiotherapy for the first time

Exclusion criteria

Exclusion criteria: Patients with proven diabetes Patients taking anti-lipid drugs Patients taking antipsychotic drugs, including olanzapine Pregnant women

Design outcomes

Primary

Measure	Time frame
The nausea and vomiting severity. Timepoint: The before, first, third and fifth days of radiotherapy. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamdolah Sharifi

Oroumia University of Medical Sciences

Sharifi_md1992@yahoo.com+98 44 3223 4897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026